While several studies have already demonstrated a correlation between the uptake of PARP imaging agents and elevated intratumoral PARP1 expression, the clinical utility of [18F]PARPi imaging in PCa patients has yet to be fully elucidated [25, 51]. The gene discussed is PARP1; the disease is posterior cortical atrophy.